Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | FADS1 | O60427 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469138 | 0.82 | GLA (0.56) | P2RX1LMNAKMT2AMEN1POLB | |
| SCHEMBL6451241 | 0.76 | TMPRSS4 (0.51) | TMPRSS4P2RX1LMNAKMT2AMEN1 | |
| SCHEMBL25350656 | 0.76 | TMPRSS4 (0.65) | TMPRSS4P2RX1KMT2AMEN1FADS1 | |
| SCHEMBL11125942 | 0.74 | ALDH1A1 (0.57) | LMNAKMT2AMEN1MAPK1GLA | |
| SCHEMBL11125943 | 0.74 | ALDH1A1 (0.57) | LMNAKMT2AMEN1MAPK1GLA | |
| SCHEMBL330643 | 0.73 | TMPRSS4 (0.69) | TMPRSS4P2RX1KMT2AMEN1HPGD | |
| SCHEMBL17111063 | 0.72 | ALDH1A1 (0.56) | LMNAKMT2AMEN1MAPK1GLA | |
| SCHEMBL4125681 | 0.72 | MAPK1 (0.59) | LMNAKMT2AMEN1MAPK1GLA | |
| SCHEMBL31338969 | 0.72 | MAPK1 (0.59) | LMNAKMT2AMEN1MAPK1GLA | |
| SCHEMBL2169418 | 0.71 | PKM (0.57) | LMNAKMT2AMEN1MAPK1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | TMPRSS4 1403/4885P2RX1 2051/4885LMNA 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.